Literature DB >> 24402595

Absorbable mesh augmentation compared with no mesh for anterior prolapse: a randomized controlled trial.

Magali Robert1, Isabelle Girard, Erin Brennand, Selphee Tang, Colin Birch, Magnus Murphy, Sue Ross.   

Abstract

OBJECTIVE: To compare anatomical and patient-reported outcomes at 12 months postoperatively for women who had anterior compartment pelvic organ prolapse (POP) surgery using a repair augmented with porcine small intestine submucosa mesh (Mesh Group) compared with those who had a native tissue repair (No Mesh Group).
METHODS: This was a randomized controlled trial with 12 months follow-up. The surgical procedure was identical in both groups except for the placement of intervening mesh. The primary outcome was anatomical "cure" (Ba of -1 or less on Pelvic Organ Prolapse Quantification [POP-Q]). Secondary outcomes included POP-Q stage, patient-reported outcomes, and patient satisfaction. The study was powered to detect a 40% difference at 80% power (α=0.05).
RESULTS: Fifty-seven women were randomized (28 to Mesh Group, 29 to No Mesh Group). Forty-five (79%) underwent concomitant surgery. At the 12-month follow-up, 56% (15/27) in the Mesh Group and 61% (17/28) in the No Mesh Group were considered cured (relative risk 0.90, 95% confidence interval 0.52-1.54). There were no significant differences between groups in recurrent or persistent prolapse (7% in each group) nor in patient-reported outcomes at 12 months. Pelvic girdle pain occurred in 4 of 27 in the Mesh Group and 3 of 28 in the No Mesh Group.
CONCLUSION: No significant differences were observed in anatomical or patient-reported outcomes outcome parameters at 12 months after correction of symptomatic anterior POP by mesh or no mesh repair. In our study, porcine small intestine submucosa mesh did not confer additional benefit over a native tissue repair. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT0095544. LEVEL OF EVEDIENCE: I.

Entities:  

Mesh:

Year:  2014        PMID: 24402595     DOI: 10.1097/AOG.0000000000000105

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  7 in total

1.  Minimal modulation of the host immune response to SIS matrix implants by mesenchymal stem cells from the amniotic fluid.

Authors:  F Lesage; S Pranpanus; F M Bosisio; M Jacobs; S Ospitalieri; J Toelen; J Deprest
Journal:  Hernia       Date:  2017-07-27       Impact factor: 4.739

Review 2.  Recurrent pelvic organ prolapse: International Urogynecological Association Research and Development Committee opinion.

Authors:  Sharif Ismail; Jonathan Duckett; Diaa Rizk; Olanrewaju Sorinola; Dorothy Kammerer-Doak; Oscar Contreras-Ortiz; Hazem Al-Mandeel; Kamil Svabik; Mitesh Parekh; Christian Phillips
Journal:  Int Urogynecol J       Date:  2016-07-05       Impact factor: 2.894

3.  Tannic acid-loaded hydrogel coating endues polypropylene mesh with hemostatic and anti-inflammatory capacity for facilitating pelvic floor repair.

Authors:  Chenghao Wu; Zixuan Zhou; Xi You; Yi Guo; Ping Chen; Huaifang Li; Xiaowen Tong
Journal:  Regen Biomater       Date:  2022-09-26

Review 4.  Prevention and management of pelvic organ prolapse.

Authors:  Ilias Giarenis; Dudley Robinson
Journal:  F1000Prime Rep       Date:  2014-09-04

Review 5.  To mesh or not to mesh: a review of pelvic organ reconstructive surgery.

Authors:  Patrick Dällenbach
Journal:  Int J Womens Health       Date:  2015-04-01

6.  Anterior colporrhaphy: a standard operation? Systematic review of the technical aspects of a common procedure in randomized controlled trials.

Authors:  Ksenia Halpern-Elenskaia; Wolfgang Umek; Barbara Bodner-Adler; Engelbert Hanzal
Journal:  Int Urogynecol J       Date:  2017-12-06       Impact factor: 2.894

7.  A systematic review of outcome and outcome-measure reporting in randomised trials evaluating surgical interventions for anterior-compartment vaginal prolapse: a call to action to develop a core outcome set.

Authors:  Constantin M Durnea; Vasilios Pergialiotis; James M N Duffy; Lina Bergstrom; Abdullatif Elfituri; Stergios K Doumouchtsis
Journal:  Int Urogynecol J       Date:  2018-10-22       Impact factor: 2.894

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.